Chemotherapy-induced peripheral neuropathy (CIPN) remains one of the major limitations in oncology clinics due to the increasing number of cancer patients, the lack of effective treatment strategies and relapse of the disease. Around 30%-40% of patients undergoing chemotherapy develop peripheral neuropathy and experience symptoms of pain and sensory disturbances.
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deficits (tingling sensations, burning pain in the arms, allodynia and hyperalgesia) to various functional deficits (impaired axonal transmission and reduced nutritive blood flow to nerves). The most common agents causing CIPN are platinum compounds (eg cisplatin), taxane derivatives, vinca alkaloids, epothilones, thalidomide, and bortezomib, which adversely affect the peripheral nervous system through dissimilar mechanisms. Although the molecular patho-mechanism and severity may vary with the inducing agent, physical damage to the neurons by chemotherapeutic agents is a common mechanism underlying the disease pathology.
Physical damage by chemotherapeutic drugs leads to functional impairment in neurons through oxidative stress, inflammation, apoptosis, and electrophysiological disturbances.
Most chemotherapeutic drugs penetrate the blood-brain barrier (BBB) poorly, but readily penetrate the blood-nerve barrier (BNB) and bind to the dorsal root ganglia (DRG) and peripheral axons. Experimental studies reveal that chemotherapeutic drugs preferentially accumulate and bind in the DRG and peripheral nerves. The blood-nerve barrier is less efficient than the BBB, specifically in the areas of the DRG and nerve terminals, which allows easier access for potential neurotoxins into the periphery. This study investigated the agent allantoin, which is a metabolic intermediate of purine catabolism that often accumulates in stressed plants, for its protective effects against neuropathy induced by the platinum compound cisplatin. A previous study used arabidopsis knockout mutants (aln) of allantoinase to show that this purine metabolite activates abscisic acid (ABA) production, thereby stimulating stress-related gene expression and enhancing seedling tolerance to abiotic stress. Allantoin is reported to activate the jasmonate signaling in a MYC2. 4 In this study, it was hypothesized that, because of its ability to cross the blood-nerve barrier and reach the areas of dorsal root ganglions and nerve terminals affected by cisplatin, allantoin has an anti-oxidant activity, reducing the potential toxic effect of cisplatin and thus reducing degeneration of the small nerve fibers. In a literature survey, allantoin has been reported to possess anti-diabetic, 5 anti-hypertensive, 6 and analgesic activity. 
| MATERIAL S AND ME THODS

| Chemicals
Cisplatin, allantoin and other chemicals were purchased from commercial supplies (Cipla, Himedia, Sigma etc). All reagents and chemicals were of analytical reagent grade.
| Experimental animals
Adult male Wistar rats weighing 160-200 g were used in the study.
Female rats were not included to rule out the influence of female sex hormones. 
| Methodology
| Animal groupings
The animals were grouped into four groups, each group containing six rats (n = 6) as follows. Group I: normal control (distilled water po for 8 weeks). Group II: cisplatin control (2 mg/kg ip for 6 weeks).
Group III: cisplatin (2 mg/kg ip for 6 weeks) + allantoin (200 mg/kg po for 8 weeks). Group IV: cisplatin (2 mg/kg ip for 6 weeks) + allantoin (400 mg/kg po for 8 weeks).
| Study protocol
Cisplatin (2 mg/kg) was administered to the rats twice a week ip for 6 weeks to induce neuropathy. 8 The dose of cisplatin was standardized in our laboratory. The protective drug allantoin (200 & 400 mg/ kg) was given orally daily from day 0 to 8 weeks using an oral feeding needle (size 16G × 1.1/2) to groups 3 and 4. The dose of allantoin was decided based on LD50 studies 9 reporting an LD50 (oral) in rats of >5000 mg/kg. After 8 weeks of treatment, blood was withdrawn from the retro-orbital sinus under light anesthesia for measurement of biochemical parameters. Behavioral studies to ascertain the preventive effect of allantoin after stopping cisplatin administration were carried out before the start of the drug regime on day 0 and after completion of the drug regime at 8 weeks. Rats were sacrificed by an overdose of anesthesia and the sciatic nerves were isolated for nerve conduction velocity tests and for checking antioxidant activity in tissue homogenates.
| Body weight measurement
Body weights were measured using a digital weighing scale (Advanturer OHAUS) before and after treatment.
| Behavioral studies
| Tail immersion test
Cold and thermal hyperalgesia was assessed by tail immersion test.
The terminal part of the tail (1 cm) was immersed in water maintained at either 46 or 4℃. The time to tail withdrawal reflex or signs of struggle were recorded as a response to hot and cold sensations and a cut-off time of 20 seconds was maintained. Rats were habituated to the testing procedure and handling by the investigator during the week before the experiment. All the animals were held in a restrainer to maintain uniform stress for all the groups. 
| Locomotor activity test
Spontaneous locomotor activity was monitored using a digital actophotometer (Techno Electronics, India) equipped with infrared sensitive photo cells. The apparatus was placed in a darkened, light-and sound-attenuated, and ventilated testing room. Each interruption of the beam on the x or y axis generated an electric impulse, which was recorded by a digital counter. Activity was measured as counts per 5 minutes. 
| Mechanical allodynia test
Mechanical allodynia was defined as a significant decrease in withdrawal thresholds in response to electronic von-Frey testing (inhouse fabricated electronic von Frey instrument). Rats were placed individually on an elevated mesh platform (1 cm 2 perforations) in a clear plastic cage and adapted to the testing environment for at least 15 minutes. To assess the withdrawal threshold of the rat hind paw, a rigid polypropylene tip mounted on the cone of the probe was used. All measurements were performed in a quiet, temperature-controlled room.
Paw withdrawal threshold measurements were standardized by using 3 out of 5 values and Positive responses were noted if the paw was robustly and immediately withdrawn. 
| Mechanical hyperalgesia test
The nociceptive flexion reflex was quantified using an in-house fabricated electronic Randall-Selitto paw pressure device which applies a linearly increasing mechanical force (in grams) to the dorsum of the rat's hindpaw. The nociceptive threshold, expressed in grams, was assessed by increasing pressure to the hind paw until a squeak (vocalisation threshold) was elicited. As this test involves animal handling, the rat was habituated to being handled as follows. Three days before the experiment rats were handled continuously for 20 seconds 2 or 3 times depending on their capacity to remain quiet. On the day of the experiment, rats were again han- 
| Measurement of haematological parameters
At the end of the experimental period, approximately 0.5 ml of blood was drawn from the retro-orbital plexus of the rats under light anaesthesia. Each blood sample was collected in a clean, dry, labelled micro-centrifuge tube containing 10% EDTA solution (0.5 ml blood).
The blood samples were analyzed within 6 hours using standard procedures for the estimation of haemoglobin, and WBC, RBC and platelet counts. and centrifuged for 10 minutes, and the resulting supernatant was used for measurement of lipid peroxide (malondialdehyde, MDA), 15 catalase activity 16 and superoxide dismutase (SOD).
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supernatant was centifuged at 3200 rpm for 20 minutes and used for measurement of reduced glutathione (GSH) 18 and nitric oxide. 
| Statistical analysis
All data were expressed as means ± SEM. One-way analysis of variance between the groups followed by Dunnett's multiple comparison test was used to assess differences between the control, cisplatin-treated and cisplatin + allantoin-treated groups. A probability value of *P < 0.05 was considered as significant, **P < 0.01 was considered as highly significant and ***P < 0.001 was considered very highly significant.
| RE SULTS
| Effect on behavioural studies
| Cold and thermal hyperalgesia
The tail withdrawal latency of control cisplatin-treated (group 2) rats was significantly lower than that of normal rats (group 1), indicating development of hyperalgesia. Treatment with allantoin (200 mg/kg) significantly increased the tail withdrawal latency compared to the cisplatin control group. At a higher dose (400 mg/kg), allantoin did not exhibit a significant effect (Figures 1 and 2 ).
| Locomotor activity
Activity measured as the number of counts/10 minutes of cisplatin control rats was significantly lower than in normal rats. Allantoin treatment at the high dose (400 mg/kg) resulted in a significant increase in activity. At the lower dose (200 mg/kg), allantoin did not exhibit any significant change compared to the cisplatin control ( Figure 3 ).
| Mechano-tactile allodynia
The paw withdrawal threshold of cisplatin control rats was significantly lower than in normal rats. Treatment with allantoin (200 mg/ kg) significantly increased the paw withdrawal threshold compared to cisplatin control rats. At the higher dose (400 mg/kg), allantoin did not exhibit a significant effect compared to the cisplatin control (Figure 4 ).
| Mechanical hyperalgesia
The mechanical paw pressure threshold of cisplatin control rats was significantly lower than in normal rats. Treatment with allantoin 
| Effect on sciatic nerve conduction velocity
The sciatic nerve conduction velocity of cisplatin control rats was significantly lower than that of normal rats. The sciatic nerve conduction velocity in rats treated with allantoin (200 and 400 mg/ kg oral) was significantly higher than in the cisplatin-treated rats ( Figure 6 ).
| Effect on haematological parameters
Haematological parameters in cisplatin-treated animals were found to be significantly altered compared to those of the normal control group (group 1). The WBC count in rats treated with allantoin (200 and 400 mg/kg oral) showed no significant changes compared to the cisplatin-treated rats. RBC counts, haemoglobin content and platelet counts in rats treated with allantoin (200 and 400 mg/kg oral) were significantly higher than in the cisplatin-treated rats (Table 1) .
| Effect on biochemical parameters
The catalase activity, superoxide dismutase activity and reduced glutathione levels of cisplatin control rats were significantly lower than in normal control rats. In rats treated with allantoin (200 mg/kg oral), the catalase activity, superoxide dismutase activity and reduced glutathione levels were significantly higher than in the cisplatin-treated rats. The malonaldehyde levels and nitric oxide concentration of cisplatin-treated rats were higher than in normal rats, while in rats treated with allantoin (200 and 400 mg/kg orally) they were significantly lower than in the cisplatin-treated rats (Table 2) .
| D ISCUSS I ON
Cisplatin is an important component of chemotherapy used against various tumour types such as pancreatic cancer, breast cancer, osteosarcoma and metastatic melanoma. However, its clinical use is severely restricted by dose-limiting neurotoxicity. As well as affecting the nervous system, cisplatin has also been reported to cause ROS generation and lipid peroxidation. Studies suggest that cisplatin reduces peripheral nerve blood supply through a potent angiogenic effect which may result in nerve damage. 20 In this study rats administered cisplatin (2 mg/kg ip weekly twice for 6 weeks) exhibited decreased bodyweight, thermal hyperalgesia, decreased motor co-ordination, mechanical allodynia, mechanical hyperalgesia, nerve conduction velocity deficits and decreased antioxidant levels, all of which are symptoms frequently hyperlgesia. This may be because of the peripheral antinociceptive activity of allantoin, which has been reported to involve activation of opioid receptor-mediated ATP-sensitive channels. 21 Thus at a high dose (400 mg/kg) allantoin may exhibit analgesic activity.
Allantoin has been shown to have significant anti-inflammatory and wound healing properties. Reports suggest that allantoin exerts antidiabetic activity in streptozotocin-induced diabetic rats by decreasing the levels of fasting blood glucose and HbAlc, while conversely increasing the levels of insulin, GLP-1, and C-peptide.
In recent reports allantoin treatment increased the serum antioxidant activities of tGSH, GSH, and SOD, but decreased the levels of MDA and GSSG. 5 These findings suggested that allantoin treatment may be able to ameliorate the effects of chronic oxidative stress in β-cells and other bodily organs.
Allantoin has also been shown to exert anti-inflammatory ef- The effects of allantoin in this study could be due to its anti-inflammatory and antioxidant activity, which may have restored motor nerve conduction velocity deficits and improved cold and thermal hyperalgesia, mechano-tactile allodynia, and mechanical hyperalgesia compared to cisplatin-treated rats. Values are expressed as means ± SEM (n = 6). The data were statistically analyzed by one-way. ANOVA followed by Dunnet's multiple comparison test. *P < 0.05 was considered as significant, **P < 0.01 was considered as highly significant and ***P < 0.001 was considered as very highly significant when compared with the cisplatin control group.
TA B L E 2 Effect of allantoin on biochemical parameters in cisplatin-treated rats
Parameters
Group 1 Normal control
haemoglobin, platelet and RBC levels were significantly increased in allantoin-treated rats compared to cisplatin-treated rats, while the WBC count in treated groups remained normal. 16 
| CON CLUS ION
Our findings suggest favourable effects of allantoin (200 mg/kg) on functional abnormalities in cisplatin neuropathy. We have shown that allantoin can ameliorate cisplatin-induced neurotoxic insults to neurons.
It therefore shows promise as an adjuvant drug in cancer treatment.
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